Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway

Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the PD-1–PDL-1 interaction. Here, we have identified novel antagonistic anti–PD-1 Abs not blocking the PD-1–PDL-1 interaction. The nonblocking Abs recognize epitopes on PD-1 located o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Med
Main Authors: Fenwick, Craig, Loredo-Varela, Juan-Luis, Joo, Victor, Pellaton, Céline, Farina, Alex, Rajah, Navina, Esteves-Leuenberger, Line, Decaillon, Thibaut, Suffiotti, Madeleine, Noto, Alessandra, Ohmiti, Khalid, Gottardo, Raphael, Weissenhorn, Winfried, Pantaleo, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: Rockefeller University Press 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605749/
https://ncbi.nlm.nih.gov/pubmed/31123083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20182359
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados